Zobrazeno 1 - 10
of 31
pro vyhledávání: ''
Autor:
Thomas Roeder, Lia Burkhardt, Judith Bossen, Line Steen, Iris Bruchhaus, Karin Uliczka, Christine Fink, Mandy Mong-Quyen Mai, Roxana Pfefferkorn, Michael Spohn, Holger Heine
Publikováno v:
Molecular Cancer Therapeutics. 18:1659-1668
Lung cancer is the leading cause of cancer-associated mortality. Mutations in the EGFR gene are among the most important inducers of lung tumor development, but success of personalized therapies is still limited because of toxicity or developing resi
Autor:
Daniela Meco, Nadia Trivieri, Anna Lasorella, Valentina Muto, Maurizio Martini, Marco Tartaglia, Matteo Lucchini, Alessandro Bruselles, Andrea Ciolfi, Massimo Caldarelli, Massimiliano Mirabella, Tiziana Servidei, Riccardo Riccardi, Roberta Morosetti
Publikováno v:
Cancer Research. 77:5860-5872
The basis for molecular and cellular heterogeneity in ependymomas of the central nervous system is not understood. This study suggests a basis for this phenomenon in the selection for mitogen-independent (MI) stem-like cells with impaired proliferati
Publikováno v:
Cancer Research. 80:4490-4490
Objective: Lung cancer is one of the leading causes of cancer-related mortality in the world, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. With the emergence of epidermal growth factor receptor tyrosine k
Publikováno v:
Cancer Immunology Research. 8:B57-B57
Objective: Non-small cell lung cancer (NSCLC) patients with specific EGFR mutations benefited from the emergence of EGFR tyrosine kinase inhibitors (EGFR-TKIs). Unfortunately, almost all cases eventually recrudesced after a median of 10 months. Thera
Publikováno v:
Cancer Research. 78:894-894
Non-small cell lung cancer (NSCLC) is a major type of lung cancer which accounts for approximately 80-85% of all lung cancers. Epidermal growth factor receptor (EGFR)- targeted tyrosine kinase inhibitors (TKIs), such as gefitinib have improved the su
Publikováno v:
Clinical Cancer Research. 15:7502-7509
Gefitinib and erlotinib are ATP competitive inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase and are approved around the world for the treatment of patients with non-small cell lung cancer (NSCLC). Somatic mutations in the EG
Autor:
John V. Heymach, Eugene Lifshits, George N. Naumov, Tina Cascone, Daniel G. Tenen, Bruce E. Johnson, Lars A. Akslen, Jeffrey A. Engelman, Monique B. Nilsson, Hua Kang Wu, Oddbjørn Straume, Pasi A. Jänne, Beow Y. Yeap, Balazs Halmos, Xi M. Tang, Alexandra Briggs, Judah Folkman, Lauren Averett Byers, Li Xu, Susumu Kobayashi
Publikováno v:
Clinical Cancer Research. 15:3484-3494
Purpose: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) gefitinib and erlotinib benefit some non–small cell lung cancer (NSCLC) patients, but most do not respond (primary resistance) and those who initially respond eve
Autor:
Adi F. Gazdar, Luc Girard, Michael D. Story, Robert Graves, Michael Peyton, Mitsuo Sato, Stella Redpath, John D. Minna, Jerry W. Shay, Amit K. Das, Chaitanya S. Nirodi
Publikováno v:
Cancer Research. 66:9601-9608
Non–small cell lung cancers (NSCLCs) bearing mutations in the tyrosine kinase domain (TKD) of the epidermal growth factor receptor (EGFR) often exhibit dramatic sensitivity to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. Ionizing ra
Autor:
Victoria A. Joshi, Pasi A. Jänne, Thomas J. Lynch, Peter Verlander, Panos Fidias, Bruce E. Johnson, Daniel A. Haber, Jeffrey C. Lee, Eugene J. Mark, Neal I. Lindeman, Matthew Meyerson, Daphne W. Bell, Raju Kucherlapati, David N. Louis, Lecia V. Sequist, Janina A. Longtine
Publikováno v:
Clinical Cancer Research. 12:4403s-4408s
As the literature about epidermal growth factor receptor (EGFR) mutations grows and screening for mutations becomes increasingly integrated into clinical care, it is important to examine how best to do somatic mutational analyses and how best to use
Publikováno v:
Cancer Research. 66:3162-3168
Somatic mutations in the epidermal growth factor receptor (EGFR) occur frequently in lung cancer and confer sensitivity to EGFR kinase inhibitors gefitinib and erlotinib. These mutations, which occur in the kinase domain of the protein, also render E